SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation....
Read More Details
Finally We wish PressBee provided you with enough information of ( IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance )
Also on site :
- Costco's Sturdy New Bookshelf Is So Stunning, Shoppers are Buying 2 at a Time
- Israel Recovers Bodies of Three Hostages Held by Hamas in Gaza
- Grammy-Winning Hitmaker Declines Fan's Luxe Gift, Offers Unforgettable Experience